BR112017011724A2 - ensaio para detectar dpp-4 humana - Google Patents

ensaio para detectar dpp-4 humana

Info

Publication number
BR112017011724A2
BR112017011724A2 BR112017011724-0A BR112017011724A BR112017011724A2 BR 112017011724 A2 BR112017011724 A2 BR 112017011724A2 BR 112017011724 A BR112017011724 A BR 112017011724A BR 112017011724 A2 BR112017011724 A2 BR 112017011724A2
Authority
BR
Brazil
Prior art keywords
assay
dpp
detect human
human dpp
antibodies
Prior art date
Application number
BR112017011724-0A
Other languages
English (en)
Inventor
Chang Chien-Ying
Xiao Xiaodong
Chowdhury Partha
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Publication of BR112017011724A2 publication Critical patent/BR112017011724A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

esta invenção fornece um ensaio robusto, sensível, e específico para a detecção e medição de níveis de dpp-4 em amostras obtidas de pacientes humanos. a invenção fornece ainda novos anticorpos monoclonais anti-dpp-4 que reconhecem dpp-4 humana, e kits de ensaio compreendendo um ou mais destes anticorpos.
BR112017011724-0A 2015-01-09 2016-01-08 ensaio para detectar dpp-4 humana BR112017011724A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101697P 2015-01-09 2015-01-09
US62/101,697 2015-01-09
PCT/US2016/012603 WO2016112261A2 (en) 2015-01-09 2016-01-08 Assay to detect human dpp-4

Publications (1)

Publication Number Publication Date
BR112017011724A2 true BR112017011724A2 (pt) 2018-05-15

Family

ID=56356576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011724-0A BR112017011724A2 (pt) 2015-01-09 2016-01-08 ensaio para detectar dpp-4 humana

Country Status (14)

Country Link
US (2) US10351630B2 (pt)
EP (1) EP3242686B1 (pt)
JP (1) JP2018502577A (pt)
KR (1) KR20170098941A (pt)
CN (1) CN107206079A (pt)
AU (1) AU2016205188A1 (pt)
BR (1) BR112017011724A2 (pt)
CA (1) CA2970540A1 (pt)
HK (2) HK1243953A1 (pt)
IL (1) IL252528A0 (pt)
MX (1) MX2017008748A (pt)
RU (1) RU2017127182A (pt)
SG (1) SG11201705598VA (pt)
WO (1) WO2016112261A2 (pt)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US7115555B2 (en) * 1998-07-09 2006-10-03 Baylor College Of Medicine Hypohidrotic ectodermal dysplasia genes and proteins
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
WO2002092127A1 (en) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP1631680A2 (en) 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
KR20080039929A (ko) * 2005-07-22 2008-05-07 와이스 테라퓨틱스 가부시키가이샤 항-ｃｄ26 항체 및 이들의 사용 방법
US20090155784A1 (en) 2007-01-22 2009-06-18 Wyeth Assessment of asthma and allergen-dependent gene expression
AU2009231733B2 (en) 2008-03-31 2015-12-24 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20130310266A1 (en) * 2010-09-03 2013-11-21 Immport Therapeutics, Inc. Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
CN103328506A (zh) 2010-10-15 2013-09-25 米迪缪尼有限公司 用于改善肺功能的疗法
BR112013013460A8 (pt) 2010-12-16 2019-02-12 Genentech Inc métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total
US8961965B2 (en) 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
BR112016017192A2 (pt) 2014-01-27 2017-10-10 Medimmune Llc dipeptidil peptidase-4 (dpp4/cd26) como um biomarcador periférico da ativação de il-13 no pulmão asmático

Also Published As

Publication number Publication date
CA2970540A1 (en) 2016-07-14
US20160200832A1 (en) 2016-07-14
AU2016205188A1 (en) 2017-06-22
RU2017127182A (ru) 2019-02-11
EP3242686B1 (en) 2020-07-08
HK1243953A1 (zh) 2018-07-27
CN107206079A (zh) 2017-09-26
WO2016112261A2 (en) 2016-07-14
SG11201705598VA (en) 2017-08-30
US20190352425A1 (en) 2019-11-21
EP3242686A2 (en) 2017-11-15
MX2017008748A (es) 2017-11-17
IL252528A0 (en) 2017-07-31
US10351630B2 (en) 2019-07-16
JP2018502577A (ja) 2018-02-01
WO2016112261A3 (en) 2016-09-01
KR20170098941A (ko) 2017-08-30
HK1244444A1 (zh) 2018-08-10
EP3242686A4 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
BR112016029521A2 (pt) ?kit, dispositivo e método para a detecção de câncer de estômago?
BR112016027475A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático
BR112014031365A2 (pt) métodos de detectar doenças ou condições
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
BR112016028944A2 (pt) kit ou dispositivo para a detecção de câncer do trato biliar e método de detecção
BR112017025297A2 (pt) anticorpos anti-gitr para diagnóstico do câncer
MA55868A (fr) Anticorps monoclonal anti-ctla4 ou son fragment se liant à l'antigène, composition pharmaceutique et son utilisation
BR112016029634A2 (pt) kit, dispositivo e método para a detecção de câncer de fígado
MA40390A (fr) Procédés d'analyse impliquant des nanoparticules dissociables
BR112016025627A2 (pt) biomarcadores e combinações dos mesmos para diagnóstico de tuberculose
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
BR112016004305A2 (pt) métodos diagnósticos e composições para tratamento de glioblastoma
MX2020000186A (es) Ensayos para evaluar los niveles de anticuerpos neutralizantes en sujetos tratados con un fármaco biológico y usos de los mismos en medicina personalizada.
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112017023726A2 (pt) detecção de fatores de virulência microbiana na cavidade oral
BR112018010764A2 (pt) método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente
EA201700208A1 (ru) Способ и устройство для обнаружения малярии
BR112017021186A2 (pt) ?método para detectar a presença de bactérias produtoras de beta-lactamase?
BR112016017926A2 (pt) ensaio para detectar periostina humana
BR112018013381A2 (pt) anticorpo especificamente ligante a antígenos derivados de miobacteria ou fragmento ligante a antígeno do mesmo
WO2014151290A3 (en) Assay for predictive biomarkers
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
EP3353697A4 (en) ANALYSIS OF MULTIPLE RECORDINGS FOR DETERMINING THE PRESENCE OR NON-PRESENCE OF TARGET ANALYSTS

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]